These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
323 related articles for article (PubMed ID: 15629872)
1. Randomized double-blind comparison of serotonergic (Citalopram) versus noradrenergic (Reboxetine) reuptake inhibitors in outpatients with somatoform, DSM-IV-TR pain disorder. Aragona M; Bancheri L; Perinelli D; Tarsitani L; Pizzimenti A; Conte A; Inghilleri M Eur J Pain; 2005 Feb; 9(1):33-8. PubMed ID: 15629872 [TBL] [Abstract][Full Text] [Related]
2. Comparison of the effectiveness of reboxetine versus fluoxetine in patients with atypical depression: a single-blind, randomized clinical trial. Taner E; Demir EY; Cosar B Adv Ther; 2006; 23(6):974-87. PubMed ID: 17276965 [TBL] [Abstract][Full Text] [Related]
3. Differential prediction of first clinical response to serotonergic and noradrenergic antidepressants using the loudness dependence of auditory evoked potentials in patients with major depressive disorder. Juckel G; Pogarell O; Augustin H; Mulert C; Müller-Siecheneder F; Frodl T; Mavrogiorgou P; Hegerl U J Clin Psychiatry; 2007 Aug; 68(8):1206-12. PubMed ID: 17854244 [TBL] [Abstract][Full Text] [Related]
4. Severity of depression and response to antidepressants: GENPOD randomised controlled trial. Wiles NJ; Mulligan J; Peters TJ; Cowen PJ; Mason V; Nutt D; Sharp D; Tallon D; Thomas L; O'Donovan MC; Lewis G Br J Psychiatry; 2012 Feb; 200(2):130-6. PubMed ID: 22194183 [TBL] [Abstract][Full Text] [Related]
5. Differential effects of reboxetine and citalopram on hand-motor function in patients suffering from major depression. Hegerl U; Mergl R; Henkel V; Pogarell O; Müller-Siecheneder F; Frodl T; Juckel G Psychopharmacology (Berl); 2005 Feb; 178(1):58-66. PubMed ID: 15316714 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of reboxetine compared with citalopram: a double-blind study in patients with major depressive disorder. Langworth S; Bodlund O; Agren H J Clin Psychopharmacol; 2006 Apr; 26(2):121-7. PubMed ID: 16633139 [TBL] [Abstract][Full Text] [Related]
7. Prediction of the response to citalopram and reboxetine in post-stroke depressed patients. Rampello L; Chiechio S; Nicoletti G; Alvano A; Vecchio I; Raffaele R; Malaguarnera M Psychopharmacology (Berl); 2004 Apr; 173(1-2):73-8. PubMed ID: 14685645 [TBL] [Abstract][Full Text] [Related]
8. Different gender response to serotonergic and noradrenergic antidepressants. A comparative study of the efficacy of citalopram and reboxetine. Berlanga C; Flores-Ramos M J Affect Disord; 2006 Oct; 95(1-3):119-23. PubMed ID: 16782204 [TBL] [Abstract][Full Text] [Related]
9. Reboxetine and citalopram in panic disorder: a single-blind, cross-over, flexible-dose pilot study. Seedat S; van Rheede van Oudtshoorn E; Muller JE; Mohr N; Stein DJ Int Clin Psychopharmacol; 2003 Sep; 18(5):279-84. PubMed ID: 12920388 [TBL] [Abstract][Full Text] [Related]
10. No effects of antidepressants on negative symptoms in schizophrenia. Hinkelmann K; Yassouridis A; Kellner M; Jahn H; Wiedemann K; Raedler TJ J Clin Psychopharmacol; 2013 Oct; 33(5):686-90. PubMed ID: 23857309 [TBL] [Abstract][Full Text] [Related]
11. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor. Lenox-Smith AJ; Jiang Q Int Clin Psychopharmacol; 2008 May; 23(3):113-9. PubMed ID: 18408525 [TBL] [Abstract][Full Text] [Related]
12. Noradrenaline-selective versus serotonin-selective antidepressant therapy: differential effects on social functioning. Dubini A; Bosc M; Polin V J Psychopharmacol; 1997; 11(4 Suppl):S17-23. PubMed ID: 9438229 [TBL] [Abstract][Full Text] [Related]
13. Citalopram plus reboxetine in treatment-resistant obsessive-compulsive disorder. Fontenelle LF; Mendlowicz MV; Miguel EC; Versiani M World J Biol Psychiatry; 2005; 6(1):57-9. PubMed ID: 16097406 [TBL] [Abstract][Full Text] [Related]
14. Increased positive versus negative affective perception and memory in healthy volunteers following selective serotonin and norepinephrine reuptake inhibition. Harmer CJ; Shelley NC; Cowen PJ; Goodwin GM Am J Psychiatry; 2004 Jul; 161(7):1256-63. PubMed ID: 15229059 [TBL] [Abstract][Full Text] [Related]
15. Sex differences in depressive symptoms and tolerability after treatment with selective serotonin reuptake inhibitor antidepressants: Secondary analyses of the GENPOD trial. Gougoulaki M; Lewis G; Nutt DJ; Peters TJ; Wiles NJ; Lewis G J Psychopharmacol; 2021 Aug; 35(8):919-927. PubMed ID: 33637001 [TBL] [Abstract][Full Text] [Related]
16. Nicotine, but not mecamylamine, enhances antidepressant-like effects of citalopram and reboxetine in the mouse forced swim and tail suspension tests. Andreasen JT; Redrobe JP Behav Brain Res; 2009 Jan; 197(1):150-6. PubMed ID: 18786574 [TBL] [Abstract][Full Text] [Related]
17. Diminished neural processing of aversive and rewarding stimuli during selective serotonin reuptake inhibitor treatment. McCabe C; Mishor Z; Cowen PJ; Harmer CJ Biol Psychiatry; 2010 Mar; 67(5):439-45. PubMed ID: 20034615 [TBL] [Abstract][Full Text] [Related]
18. Adverse effects from antidepressant treatment: randomised controlled trial of 601 depressed individuals. Crawford AA; Lewis S; Nutt D; Peters TJ; Cowen P; O'Donovan MC; Wiles N; Lewis G Psychopharmacology (Berl); 2014 Aug; 231(15):2921-31. PubMed ID: 24525810 [TBL] [Abstract][Full Text] [Related]
19. Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder. Versiani M; Cassano G; Perugi G; Benedetti A; Mastalli L; Nardi A; Savino M J Clin Psychiatry; 2002 Jan; 63(1):31-7. PubMed ID: 11838623 [TBL] [Abstract][Full Text] [Related]
20. [Comparison of reboxetine and sertraline in terms of efficacy and safety in major depressive disorder]. Eker SS; Akkaya C; Akgöz S; Sarandöl A; Kirli S Turk Psikiyatri Derg; 2005; 16(3):153-63. PubMed ID: 16180148 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]